Loading
Every dated change on the records linked to Rhabdomyosarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
VA ± reduced cyclophosphamide for 22-24 weeks; radiotherapy for microscopic residual disease.
VAC (or VAC/VI) 42 weeks with radiotherapy at week 13 (COG); IVA with maintenance vinorelbine-cyclophosphamide 6 months (EpSSG); temsirolimus-VAC/VI per ARST1431 where adopted.